```html

Urticaria (Physical) – A Patient‑Friendly Guide

What is Urticaria (Physical)?

Urticaria, commonly known as hives, is a skin reaction that appears as raised, itchy welts that can vary in size from a few millimeters to several centimeters. Physical urticaria refers to a group of hives that are triggered by an external physical stimulus rather than an allergic reaction to food, medication, or infection.

The hallmark features are:

• Sudden appearance of red or skin‑colored wheals
• Intense itching or burning sensation
• Lesions that typically last less than 24 hours in one spot, though new lesions may continue to appear
• Sometimes a surrounding area of swelling (angio‑edema)

Physical urticaria can be chronic (lasting > 6 weeks) or acute (lasting < 6 weeks). It is often under‑diagnosed because the triggers are not always obvious.

Common Causes

Physical urticaria is a reaction to mechanical, thermal, or environmental stimuli. Below are the most frequently reported triggers:

• Dermatographism (skin writing): Rubbing or scratching the skin causes linear wheals.
• Cold urticaria: Exposure to cold air, water, or objects.
• Heat urticaria: Prolonged heat, hot showers, or heating pads.
• Solar (photosensitive) urticaria: Sunlight or artificial UV light.
• Vibratory or pressure urticaria: Tight clothing, watches, or repeated pressure.
• Cholinergic urticaria: Elevated body temperature from exercise, hot baths, or emotional stress.
• Water‑induced urticaria (aquagenic): Contact with plain water.
• Exercise‑induced urticaria: Physical activity without a clear allergic trigger.
• Contact urticaria: Direct skin contact with chemicals, latex, or certain plants.
• Idiopathic chronic physical urticaria: No identifiable trigger despite thorough evaluation.

Associated Symptoms

While the primary complaint is the itchy wheal, other symptoms may accompany physical urticaria, depending on the type and severity:

• Swelling of lips, eyelids, or fingers (angio‑edema)
• Burning or stinging sensation instead of itching
• Generalized flushing or redness of the skin
• Difficulty breathing or throat tightness (rare, but signals a systemic reaction)
• Headache, dizziness, or faintness after a severe episode
• Ocular symptoms such as watery eyes or itching (especially with solar urticaria)

When to See a Doctor

Most episodes of physical urticaria are benign, but medical evaluation is warranted when any of the following occur:

• Lesions persist longer than 24 hours in the same location.
• Signs of angio‑edema, especially in the face, tongue, or airway.
• Difficulty breathing, wheezing, or a feeling of throat tightness.
• Episodes are frequent (more than twice a week) or last for weeks to months.
• Symptoms do not improve with over‑the‑counter antihistamines.
• You have a known chronic condition (e.g., autoimmune disease) that could be linked to urticaria.
• Pregnancy, breastfeeding, or use of other prescription medications that may interact with treatments.

Prompt medical care can prevent complications, identify underlying disorders, and provide effective symptom control.

Diagnosis

Diagnosis is primarily clinical but may involve several steps to confirm the physical trigger and rule out other conditions.

1. Detailed History

• Onset, duration, and pattern of wheals.
• Specific physical triggers (cold, heat, pressure, sunlight, etc.).
• Associated systemic symptoms.
• Medication, food, or environmental exposures.
• Personal or family history of allergies, autoimmune disease, or thyroid problems.

2. Physical Examination

• Inspection of lesions (shape, size, distribution).
• Provocation tests: e.g., ice cube test for cold urticaria, rubbing the forearm for dermatographism.

3. Laboratory Tests (when indicated)

• Complete blood count (CBC) – to look for eosinophilia.
• Serum thyroid‑stimulating hormone (TSH) – thyroid disease is linked to chronic urticaria.
• Autoimmune panels (ANA) if systemic disease is suspected.
• Complement levels (C4) for urticarial vasculitis.

4. Specialized Tests

• Cold stimulation test (immersing a hand in ice water for 5 min).
• Phototesting for solar urticaria.
• Exercise challenge under medical supervision for exercise‑induced urticaria.

Reference: Mayo Clinic. “Urticaria (Hives).” 2023; American Academy of Dermatology guidelines, 2022.

Treatment Options

Treatment goals are to relieve itching, reduce wheal formation, and prevent complications. Therapy is usually stepped‑wise, beginning with the least invasive measures.

1. First‑Line Medications

• Second‑generation nonsedating antihistamines (e.g., cetirizine 10 mg daily, loratadine 10 mg, fexofenadine 180 mg). These are preferred because they cause minimal drowsiness.
• If symptoms persist after a week, the dose may be increased up to 2–4× the standard dose under physician guidance (off‑label but supported by studies).

2. Second‑Line Options

• H1 antihistamine + H2 blocker (e.g., famotidine 20 mg) for added control.
• Leukotriene receptor antagonists (montelukast 10 mg nightly) especially helpful in cholinergic or exercise‑induced urticaria.
• Corticosteroids (short courses of oral prednisone 0.5 mg/kg) for severe flares, not for long‑term use due to side‑effects.

3. Third‑Line / Refractory Therapy

• Omalizumab (Xolair™) – a monoclonal antibody that binds IgE; FDA‑approved for chronic spontaneous urticaria and increasingly used for physical urticaria resistant to antihistamines.
• Cyclosporine (3‑5 mg/kg/day) – immunomodulator for severe, antihistamine‑refractory cases; requires close monitoring of kidney function and blood pressure.
• Other emerging biologics (e.g., dupilumab) are under investigation.

4. Non‑Pharmacologic Measures

• Identify and avoid known triggers (e.g., keep a temperature diary for cold/heat urticaria).
• Apply cool compresses to soothe itching; avoid hot showers.
• Wear loose, breathable clothing and avoid tight accessories that cause pressure urticaria.
• For solar urticaria, use broad‑spectrum sunscreen with a high SPF and UV‑protective clothing.
• Gradual desensitization protocols (e.g., controlled cold exposure) may be recommended by an allergist for cold urticaria.

All treatment decisions should be individualized. Discuss medication side‑effects and any underlying conditions with your health‑care provider.

Prevention Tips

Even though some forms of physical urticaria are unavoidable, many flares can be prevented with lifestyle adjustments:

• Know your trigger: Keep a symptom journal noting temperature, activities, clothing, and foods.
• Temperature management:
  • For cold urticaria – carry a pocket‑size “cold kit” (gloves, scarf, warm water bottle) and avoid rapid temperature changes.
  • For heat urticaria – use air‑conditioning, cool showers, and stay hydrated.
• Stress reduction: Stress can amplify cholinergic urticaria. Practice relaxation techniques (deep breathing, yoga, mindfulness).
• Exercise wisely: Warm up slowly, wear moisture‑wicking fabrics, and cool down gradually.
• Skin care: Use fragrance‑free moisturizers to maintain barrier integrity; avoid harsh soaps that may irritate the skin.
• Sun protection: Broad‑spectrum sunscreen applied 15 minutes before outdoors, reapply every 2 hours, and wear hats and UV‑blocking sunglasses.
• Medication adherence: Take antihistamines regularly, not only when symptoms appear, to maintain steady blood levels.
• Medical follow‑up: Annual review with an allergist or dermatologist if you have chronic physical urticaria.

Emergency Warning Signs

Bottom Line

Physical urticaria is a common, often distressing skin condition triggered by external physical factors such as temperature changes, pressure, or sunlight. While most cases are manageable with antihistamines and trigger avoidance, chronic or severe episodes may require advanced therapies like omalizumab or short courses of steroids. Recognizing warning signs—especially those indicating anaphylaxis—is crucial and warrants urgent medical care.

For personalized advice, always consult a qualified health‑care professional. The information above reflects current recommendations from reputable sources including the Mayo Clinic, CDC, NIH, WHO, and the American Academy of Dermatology (2022‑2024).

```